Cart
sales@molnova.com
TMB-PS
CAS No. 102062-36-2
TMB-PS( TMBZ-PS )
Catalog No. M20508 CAS No. 102062-36-2
TMB-PS is a chromogenic reagent for the detection of hydrogen peroxide e.g. in the enzymatic analysis of body fluids.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 50MG | 31 | In Stock |
|
| 100MG | 45 | In Stock |
|
| 200MG | 63 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTMB-PS
-
NoteResearch use only, not for human use.
-
Brief DescriptionTMB-PS is a chromogenic reagent for the detection of hydrogen peroxide e.g. in the enzymatic analysis of body fluids.
-
DescriptionTMB-PS is a chromogenic reagent for the detection of hydrogen peroxide e.g. in the enzymatic analysis of body fluids.
-
In Vitro——
-
In Vivo——
-
SynonymsTMBZ-PS
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number102062-36-2
-
Formula Weight362.49
-
Molecular FormulaC19H26N2O3S?
-
Purity>98% (HPLC)
-
SolubilityDMSO:35 mg/mL (96.55 mM)
-
SMILESCc1cc(cc(C)c1N)-c1cc(C)c(NCCCS(O)(=O)=O)c(C)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Shiobara T Teshima N Kurihara M et al. Catalytic flow injection determination of vanadium by oxidation of N-(3-sulfopropyl)-33′55′-tetramethylbenzidine using bromate[J]. Talanta 1999 49(5):1083-1089.
molnova catalog
related products
-
Logmalicids B
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research.
-
Rozanolixizumab
Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
